UBS AG upgraded shares of Illumina (NASDAQ: ILMN) from a neutral rating to a buy rating in a research report sent to investors on Monday morning.
Shares of Illumina traded up 0.73% during mid-day trading on Monday, hitting $53.66. Illumina has a one year low of $37.77 and a one year high of $57.00. The stock’s 50-day moving average is currently $50.85. The company has a market cap of $6.656 billion and a P/E ratio of 47.14.
ILMN has been the subject of a number of other recent research reports. Analysts at Credit Suisse cut their price target on shares of Illumina to $59.00 in a research note to investors on Tuesday, January 29th. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Illumina from $45.00 to $48.00 in a research note to investors on Tuesday, January 29th. They now have a hold rating on the stock. Finally, analysts at Cowen reiterated an outperform rating on shares of Illumina in a research note to investors on Tuesday, January 29th.
Ten equities research analysts have rated the stock with a buy rating, fourteen have assigned a hold rating, and one has assigned an underweight rating to the company. Illumina currently has an average rating of overweight and a consensus target price of $55.00.
Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
